- Stocks
- Healthcare
- NASDAQ: CSTL

Price (delayed)

$73.46

Market cap

$1.84B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.73

Enterprise value

$1.43B

The debt has shrunk by 100% YoY

Castle Biosciences's quick ratio has increased by 18% QoQ

CSTL's EPS has dropped by 78% year-on-year and by 35% since the previous quarter

The net income has declined by 47% since the previous quarter

What are the main financial stats of CSTL

Market
Valuations
Earnings

Shares outstanding

25.06M

Market cap

$1.84B

Enterprise value

$1.43B

Price to earnings (P/E)

N/A

Price to book (P/B)

4.38

Price to sales (P/S)

26.89

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

21.07

Revenue

$68.04M

EBIT

-$13.18M

EBITDA

-$12.57M

Free cash flow

$1.49M

Per share
Balance sheet
Liquidity

EPS

-$0.73

Free cash flow per share

$0.06

Book value per share

$16.76

Revenue per share

$2.73

TBVPS

$17.56

Total assets

$437.33M

Total liabilities

$18.75M

Debt

$0

Equity

$418.59M

Working capital

$409.09M

Debt to equity

0

Current ratio

24.27

Quick ratio

24.03

Net debt/EBITDA

32.39

Margins
Efficiency
Dividend

EBITDA margin

-18.5%

Gross margin

84.8%

Net margin

-22.2%

Operating margin

-17.4%

Return on assets

-4.7%

Return on equity

-5.2%

Return on invested capital

-89%

Return on capital employed

-3.1%

Return on sales

-19.4%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Castle Biosciences stock price performed over time

Intraday

-3.47%

1 week

2.18%

1 month

24.76%

1 year

71.04%

YTD

9.4%

QTD

7.3%

How have Castle Biosciences's revenue and profit performed over time

Revenue

$68.04M

Gross profit

$57.72M

Operating income

-$11.86M

Net income

-$15.13M

Gross margin

84.8%

Net margin

-22.2%

The operating income has plunged by 81% from the previous quarter

The operating margin has dropped by 67% since the previous quarter

The net income has declined by 47% since the previous quarter

The net margin has decreased by 35% QoQ

What is Castle Biosciences's growth rate over time

What is Castle Biosciences stock price valuation

P/E

N/A

P/B

4.38

P/S

26.89

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

21.07

CSTL's EPS has dropped by 78% year-on-year and by 35% since the previous quarter

The P/S is 49% above the last 4 quarters average of 18.1

CSTL's revenue is up by 12% YoY and by 9% from the previous quarter

How efficient is Castle Biosciences business performance

Castle Biosciences's return on assets has shrunk by 177% YoY and by 12% QoQ

The ROE has shrunk by 145% YoY and by 4% QoQ

Castle Biosciences's return on invested capital has shrunk by 130% QoQ

CSTL's return on sales has dropped by 60% since the previous quarter

What is CSTL's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for CSTL.

How did Castle Biosciences financials performed over time

The total liabilities has declined by 42% year-on-year and by 21% since the previous quarter

CSTL's current ratio is up by 18% since the previous quarter

The debt is 100% lower than the equity

The debt has shrunk by 100% YoY

CSTL's debt to equity has dropped by 100% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.